|
1
|
Papac RJ: Bone marrow metastases. A
review. Cancer. 74:2403–2413. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hayes DF: Prognostic and predictive
factors revisited. Breast. 14:493–499. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kobayashi M, Okabayashi T, Sano T and
Araki K: Metastatic bone cancer as a recurrence of early gastric
cancer-characteristics and possible mechanisms. World J
Gastroenterol. 11:5587–5591. 2005.PubMed/NCBI
|
|
4
|
Wiedswang G, Borgen E, Kåresen R, Kvalheim
G, Nesland JM, Qvist H, Schlichting E, Sauer T, Janbu J, Harbitz T
and Naume B: Detection of isolated tumor cells in bone marrow is an
independent prognostic factor in breast cancer. J Clin Oncol.
21:3469–3478. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Haggar FA and Boushey RP: Colorectal
cancer epidemiology: Incidence, mortality, survival, and risk
factors. Clin Colon Rectal Surg. 22:191–197. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shah SM, Rosenthal MH, Griffin GK,
Jacobsen ED and McCleary NJ: An aggressive presentation of
colorectal cancer with an atypical lymphoproliferative pattern of
metastatic disease: A case report and review of the literature.
Clin Colorectal Cancer. 13:e5–e11. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lee JL, Lee JH, Kim MK, Cho HS, Bae YK,
Cho KH, Bae SH, Ryoo HM, Lee KH and Hyun MS: A case of bone marrow
necrosis with thrombotic thrombocttopenic purpura as a
manifestation of occult colon cancer. Jpn J Clin Oncol. 34:476–480.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pleyer L, Went P, Russ G, Prinz E, Faber
V, Röwert HJ, Karlbauer R and Greil R: Massive infiltration of bone
marrow in colon carcinoma after treatment with activated protein C.
Wiener Klinische Wochenschrift. 119:254–258. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang YC, Chang PY and Yao NS: Bone marrow
necrosis caused by metastatic colon cancer. J Clin Oncol.
27:e482009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Song JY and Dwyre DM: Metastatic
adenocarcinoma involving the bone marrow. Blood. 120:31702012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wada H, Gabazza EC, Asakura H, Koike K,
Okamoto K, Maruyama I, Shiku H and Nobori T: Comparison of
diagnostic criteria For Disseminated Intravascular Coaglation
(DIC): Diagnostic criteria of the International Society of
Thrombosis and Hemostasis (ISTH) and of the Japanese Ministry of
Health and Welfare for Overt DIC. Am J Hematol. 74:17–22. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
National Cancer Institute, . Common
Terminology Criteria for Adverse Events v4.0. NIH Publication:
Number 10-5410. 2010.
|
|
13
|
Braun S, Pantel K, Müller P, Janni W, Hepp
F, Kentenich CR, Gastroph S, Wischnik A, Dimpfl T, Kindermann G, et
al: Cytokeratin-positive cells in the bone marrow and survival of
patients with stage I, II, or III breast cancer. N Engl J Med.
342:525–533. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Iguchi H: Recent aspects for disseminated
carcinomatosis of the bone marrow associated with gastric cancer:
What has been done for the past, and what will be needed in future?
World J Gastroenterol. 21:12249–12260. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pai RK, Jayachandran P, Koong AC, Chang
DT, Kwok S, Ma L, Arber DA, Balise RR, Tubbs RR, Shadrach B and Pai
RK: BRAF-mutated, microsatellite-stable adenocarcinoma of the
proximal colon: An aggressive adenocarcinoma with poor survival,
mucinous differentiation, and adverse morphologic features. Am J
Surg Pathol. 36:744–752. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Therkildsen C, Bergmann TK,
Henrichsen-Schnack T, Ladelund S and Nilbert M: The predictive
value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment
in metastatic colorectal cancer: A systematic review and
meta-analysis. Acta Oncol. 53:852–864. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sartore-Bianchi A, Martini M, Molinari F,
Veronese S, Nichelatti M, Artale S, Di Nicolantonio F, Saletti P,
De Dosso S, Mazzucchelli L, et al: PIK3CA mutations in colorectal
cancer are associated with clinical resistance to EGFR-targeted
monoclonal antibodies. Cancer Res. 69:1851–1857. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Coulombe PA and Wong P: Cytoplasmic
intermediate filaments revealed as dynamic and multipurpose
scaffolds. Nat Cell Biol. 6:699–706. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bayrak R, Yenidünya S and Haltas H:
Cytokeratin 7 and cytokeratin 20 expression in colorectal
adenocarcinomas. Pathol Res Pract. 207:156–160. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Park SY, Kim BH, Kim JH, Lee S and Kang
GH: Panels of immunohistochemical markers help determine primary
sites of metastatic adenocarcinoma. Arch Pathol Lab Med.
131:1561–1567. 2007.PubMed/NCBI
|
|
21
|
Pierga JY, Deneux L, Bonneton C,
Vincent-Salomon A, Nos C, Anract P, Magdelénat H, Pouillart P and
Thiery JP: Prognostic value of cytokeratin 19 fragment (CYFRA 21-1)
and cytokeratin-positive cells in bone marrow samples of breast
cancer patients. Int J Biol Markers. 19:23–31. 2004.PubMed/NCBI
|
|
22
|
Dalerba P, Sahoo D, Paik S, Guo X, Yothers
G, Song N, Wilcox-Fogel N, Forgó E, Rajendran PS, Miranda SP, et
al: CDX2 as a prognostic biomarker in stage II and stage III colon
cancer. N Engl J Med. 374:211–222. 2016. View Article : Google Scholar : PubMed/NCBI
|
